Please assess the completion status of the following clinical trial:

Trial Title: PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion Criteria:~* Clinical stage I, II, or III operable invasive mammary carcinoma, confirmed by histological analysis~  * Measurable residual tumor at the primary site~    * Measurable disease is defined as any mass that can be reproducibly measured by physical examination, mammogram, and/or ultrasound and can be accurately measured in at least one dimension (longest diameter to be recorded) as 10 mm (1 cm)~* Available core biopsies from the time of diagnosis~  * May include sections of paraffin-embedded material~* Scheduled to undergo surgical treatment with either segmental resection or total mastectomy~* Prior history of contralateral breast cancer allowed if patient has no evidence of recurrence of their initial primary breast cancer within the last 5 years~* HER2-positive by Herceptest (3+) or FISH~* ER-positive and/or PR-positive by IHC~Exclusion Criteria:~* Locally recurrent breast cancer~* Evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases)~PATIENT CHARACTERISTICS:~Inclusion Criteria:~* Female~* Postmenopausal, as defined by any of the following:~  * At least 55 years of age~ * Under 55 years of age and amenorrheic for at least 12 months OR follicle-stimulating hormone (FSH) values ≥ 40 IU/L and estradiol levels ≤ 20 IU/L~ * Prior bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months~* ECOG performance status 0-1~* ANC ≥ 1,000/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* AST and ALT ≤ 1.5 times ULN~* Able to swallow and retain oral medication~* Cardiac ejection fraction normal by echocardiogram (or MUGA scan if an echocardiogram cannot be performed or is inconclusive)~Exclusion Criteria:~* Premenopausal breast cancer, pregnant, or lactating~* Serious medical illness, that in the judgment of the treating physician, places the patient at high risk of operative mortality~* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel~* Ulcerative colitis~* History of other malignancy~  * Patients who have been disease-free for 5 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinomas are eligible~* Active or uncontrolled infection~* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent~* Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure~PRIOR CONCURRENT THERAPY:~Exclusion Criteria:~* Prior chemotherapy for primary breast cancer~* Tamoxifen or raloxifene as a preventive agent within the past 21 days~* Hormone replacement therapy (e.g., conjugated estrogens tablets \[Premarin\]) within the past month~* Prior therapy with anthracyclines~* Investigational drug within the past 30 days or 5 half-lives, whichever is longer~* Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, or any other biologic therapy) other than letrozole~* Concurrent treatment with an investigational agent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive Lapatinib and Letrozole once daily for two weeks, following tumor measurement patients receive Lapatinib and Letrozole once daily for 14 weeks.
- Arm II (Type: EXPERIMENTAL): Patients receive Letrozole and placebo once daily for 2 weeks, following tumor measurement patients receive Letrozole and Lapatinib once daily for 14 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).